Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma

This study is testing a personalized immune therapy for patients with pancreatic cancer who are going to have surgery. The treatment uses dendritic cells (a type of immune cell) that are engineered in the lab to stimulate the immune system to fight cancer. This vaccine is given alongside standard chemotherapy, before or after surgery, with the goal of improving long-term outcomes. **You may be eligible if...** - You are 18 or older with confirmed pancreatic adenocarcinoma that may be surgically removable (resectable or borderline resectable) - Your cancer may be treated with surgery upfront or after chemotherapy with or without radiation - Your blood counts, kidney, and liver function are within acceptable ranges - You have signed an informed consent form **You may NOT be eligible if...** - Your cancer has already spread to distant organs (metastatic) - Your organ function is significantly compromised Talk to your doctor to see if this trial is right for you.